RecruitingNCT06643208

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fujian Provincial Hospital
Principal Investigator
Maolin Yan, Doctor
Department of Hepatobiliary Pancreatic Surgery, Fujian Provincial Hospital
Intervention
TACE-HAIC, Envafolimab and Lenvatinib(drug)
Enrollment
37 target
Eligibility
18-75 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06643208 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma →

← Back to all trials